A meta-analysis and The Cancer Genome Atlas data of prostate cancer risk and prognosis using epithelial cell adhesion molecule (EpCAM) expression

Table 1 The basic characteristics of the eligible studies

First author	Country	Age	Stage	Antibodies	Positivity (IHC)	Control groups	Cancer	Control	GS (≥ 7)	GS (≤ 6)	T stage 3–4	T stage 1–2	Lymph node metastasis (Yes)	Lymph node metastasis (No)	Bone metastasis (Yes)	Bone metastasis (No)	Clinical outcome-MA
First author	Country	Age	Stage	Antibodies	Positivity (IHC)	Control groups	N (%)	N (%)	E+/N	E+/N	E+/N	E+/N	E+/N	E+/N	E+/N	E+/N	Clinical outcome-MA
Went 2006 [36]	Switzerland	NA	T1-T4	ESA, clone VU-1D9, Novocastra, Newcastle upon Tyne, UK, dilution 1: 50	> 70%		414 (87.2%)		138/168	223/246	82/89	276/321	8/10	329/378			No
Mukherjee 2009 [35]	USA	NA	NA	Abcam, cat. #11294, dilution 1:200	≥ 20%	Normal	23 (91.3%)	20 (0%)									No
Benko 2013 [23]	Croatia	65	T2-T3	ab32392, ABCAM, Cambridge, MA, dilution 1:600	≥ 40%	Benign	102 (52%)	102 (1%)									Yes
Ni 2013 [22]	Australia	NA	NA	Epitomics, Inc.dilution 1:100	≥ 25%	Benign	10 (100%)	10 (90%)									No
Ni 2013 [22]	Australia	NA	NA	Epitomics, Inc.dilution 1:100	≥ 25%	Normal	10 (100%)	10 (20%)									No
Rybalov 2014 [34]	The Netherlands	NA	T2-T4	Clone VU-1D9, Leica Biosystems, Newcastle, UK, dilution 1:100	Weak-strong		17 (82.4%)		11/14	2/2	11/14	3/3					No
Li 2015 [27]	China	NA	NA	NA	1–9 scores	Benign	63 (88.9%)	58 (0%)							20/20	2/5	No
Campos 2016 [32]	Mexico	NA	NA	clone VU-1D9, Leica Biosystems, Newcastle, UK, dilution 1:100	TIS ≥ 1		42 (50%)						21/21	0/21	19/20	0/14	No

N number of the study population, E+ positive expression, MA multivariate analysis, NA not applicable, TIS total immunostaining score, IHC immunohistochemistry

ISSN: 1471-2490